ZA202403415B - Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses - Google Patents

Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Info

Publication number
ZA202403415B
ZA202403415B ZA2024/03415A ZA202403415A ZA202403415B ZA 202403415 B ZA202403415 B ZA 202403415B ZA 2024/03415 A ZA2024/03415 A ZA 2024/03415A ZA 202403415 A ZA202403415 A ZA 202403415A ZA 202403415 B ZA202403415 B ZA 202403415B
Authority
ZA
South Africa
Prior art keywords
trpv6
human
antibodies
antibodies against
diagnostic
Prior art date
Application number
ZA2024/03415A
Other languages
English (en)
Inventor
Prevarskaya Natalia
Lehen’Kyi V’Yacheslav
Haustrate Aurélien
Original Assignee
Univ Lille
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lille, Inst Nat Sante Rech Med filed Critical Univ Lille
Publication of ZA202403415B publication Critical patent/ZA202403415B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
ZA2024/03415A 2021-10-14 2024-05-02 Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses ZA202403415B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306438 2021-10-14
PCT/EP2022/078728 WO2023062226A2 (en) 2021-10-14 2022-10-14 Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Publications (1)

Publication Number Publication Date
ZA202403415B true ZA202403415B (en) 2025-08-27

Family

ID=78820597

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/03415A ZA202403415B (en) 2021-10-14 2024-05-02 Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Country Status (9)

Country Link
US (1) US20250236666A1 (enExample)
EP (1) EP4416181A2 (enExample)
JP (1) JP2024538787A (enExample)
KR (1) KR20240099277A (enExample)
CN (1) CN118401554A (enExample)
AU (1) AU2022365387A1 (enExample)
CA (1) CA3235233A1 (enExample)
WO (1) WO2023062226A2 (enExample)
ZA (1) ZA202403415B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230132450A (ko) * 2021-01-15 2023-09-15 코히런트 바이오파마 (쑤저우), 리미티드 항trpv6 단일 클론 항체 및 그 응용
CN120590523B (zh) * 2025-06-20 2026-01-27 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种犬瘟热病毒n蛋白单克隆抗体，快速检测胶体金试纸条及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119262A2 (en) * 2004-05-27 2005-12-15 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
EP2268665B1 (en) 2008-03-19 2014-11-12 Soricimed Biopharma Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity
JP5836940B2 (ja) * 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
KR20230132450A (ko) * 2021-01-15 2023-09-15 코히런트 바이오파마 (쑤저우), 리미티드 항trpv6 단일 클론 항체 및 그 응용

Also Published As

Publication number Publication date
JP2024538787A (ja) 2024-10-23
US20250236666A1 (en) 2025-07-24
AU2022365387A1 (en) 2024-05-02
CA3235233A1 (en) 2023-04-20
KR20240099277A (ko) 2024-06-28
WO2023062226A3 (en) 2023-05-25
WO2023062226A2 (en) 2023-04-20
CN118401554A (zh) 2024-07-26
EP4416181A2 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
Basu et al. Differentiation and regulation of TH cells: a balancing act for cancer immunotherapy
Shen et al. The efficacy of third generation anti‑HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells
Zhang et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
Flynn et al. The emerging role of anti‐CD 25 directed therapies as both immune modulators and targeted agents in cancer
Peruzzi et al. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells
Patankar et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
ZA202100916B (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
Arndt et al. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
MY205758A (en) Anti-nkg2a antibodies and uses thereof
Amoury et al. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
PE20200152A1 (es) Receptores de union a antigeno mejorados
SA520420109B1 (ar) أجسام مضادة
WO2023062226A3 (en) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses
Zhang et al. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
Meng et al. ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
Dao et al. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody
Koshio et al. DEAD/H (Asp–Glu–Ala–Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells
ZA202302392B (en) Antibodies against ilt2 and use thereof
Herrmann et al. A novel T-cell engaging bi-specific antibody targeting the leukemia antigen PR1/HLA-A2